Target |
Mechanism p53 modulators [+1] |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication |
Drug Highest PhasePhase 3 |
First Approval Ctry. / Loc.- |
First Approval Date- |
Target- |
Mechanism- |
Active Org.- |
Originator Org. |
Active Indication- |
Inactive Indication |
Drug Highest PhaseDiscontinued |
First Approval Ctry. / Loc.- |
First Approval Date- |
Target- |
Mechanism- |
Active Org.- |
Originator Org. |
Active Indication- |
Inactive Indication |
Drug Highest PhaseDiscontinued |
First Approval Ctry. / Loc.- |
First Approval Date- |
Start Date01 Oct 2006 |
Sponsor / Collaborator Epimmune, Inc. [+2] |
Start Date01 Dec 2004 |
Sponsor / Collaborator |
Start Date01 Feb 2003 |
Sponsor / Collaborator |
Drug(Targets) | Indications | Global Highest Phase |
---|---|---|
CY-1503 ( Selectins ) | Respiratory Diseases More | Discontinued |
CY-1787 ( Selectins ) | Rhinitis, Allergic More | Discontinued |
CY-725 | Asthma More | Discontinued |
CY-9701 ( VCAM1 ) | Asthma More | Discontinued |
CY-1747 | Cardiovascular Diseases More | Discontinued |